In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Gender Differences in Risk Factors for Atrial Fibrillation

Session Poster Session III - Friday 08:30 - 12:30

Speaker Nobue Yagihara

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Poster Session

Authors : N Yagihara (Niigata,JP), H Watanabe (Niigata,JP), T Watanabe (Niigata,JP), Y Aizawa (Nagaoka,JP), T Minamino (Niigata,JP)

Authors:
N Yagihara1 , H Watanabe1 , T Watanabe2 , Y Aizawa3 , T Minamino1 , 1Niigata University Graduate School of Medical and Dental Sciences, Department of Cardiovascular Biology and Medicine - Niigata - Japan , 2Niigata Health Foundation - Niigata - Japan , 3Tachikawa General Hospital - Nagaoka - Japan ,

Citation:

Introduction:  There have been various risk factors for atrial fibrillation (AF) such as cardiac and non-cardiac diseases, and atherosclerotic factors (e.g., diabetes, hypertension, and obesity). The aim of this study was to investigate the gender differences in the impact of risk factors on development of AF in the general population.

Methods:  This community-based prospective observational cohort study was based upon an annual health check-up program in Niigata, Japan. The annual examination consists of interviews about medical history, physical examinations, blood examinations, urine tests, chest radiographs, and 12-lead electrocardiograms. This study included 223,877 individuals without AF at baseline who were followed more than one year (152,322 women [68%]; age, 61±12 years).

Results:  During a follow up of 5.9±2.4 years, AF developed in 1,840 men (incidence, 4.55; 95% confidence interval, 4.34-4.76) and 1,107 women (incidence, 1.21; 95% confidence interval, 1.14-1.28). Men developed AF from younger age compared to women. In women, development of AF was rare before the age of 60 years and thereafter the incidence of AF increased steeply. Among atherosclerotic risk factors, obesity and hypertension were associated with risk of development of AF in both genders. However, impaired glucose tolerance was associated with AF only in men but not in women, and low HDL-cholesterol was associated with AF only in women but not in men. Elevated triglycerides were not associated with AF in each gender. Decreased LDL-cholesterol was associated with AF in both genders, supporting the cholesterol paradox in AF as we and others have recently identified. Heart disease and metabolic syndrome were associated with increased risk of AF in both genders. Elevated uric acid was associated with AF in women but not in men, and chronic kidney disease was associated with AF in women but the association was weak in men. Non-alcoholic fatty liver disease was associated with risk of AF in women but not in men.

Conclusion:  The age-dependent trends in the incidence of AF and the effects of various risk factors on development of AF were different between men and women. Our study indicates that the pathogenic of AF is affected by gender.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are